Literature DB >> 16575424

The "delayed onset" of antipsychotic action--an idea whose time has come and gone.

Ofer Agid1, Phillip Seeman, Shitij Kapur.   

Abstract

For years, it has been known that the "onset" of the antipsychotic response is "delayed," and this notion is expressed in many major textbooks, informs clinical decisions and has even led to the search for biological markers responsible for this delayed onset. But is the onset of antipsychotic action really delayed? In this review, we bring together data from several recent studies of antipsychotic drugs that show that the onset of the antipsychotic effect is within the first day; the effect is distinguishable from behavioural sedation; is specific to antipsychotic drugs; is seen with oral and parenteral preparations; and is seen with typical and atypical antipsychotics. More anti- "psychotic" improvement is seen within the first 2 weeks than in any other 2-week period thereafter, and more improvement is seen in the first month than in the rest of the year of follow-up. This body of data convincingly refutes the notion of "delay" in the onset of antipsychotic action and suggests an "early" onset instead. The implications of this finding for clinical decision-making, mechanisms of antipsychotic action and drug discovery are discussed.

Mesh:

Substances:

Year:  2006        PMID: 16575424      PMCID: PMC1413955     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  57 in total

1.  Significant dissociation of brain and plasma kinetics with antipsychotics.

Authors:  Johannes Tauscher; C Jones; G Remington; R B Zipursky; S Kapur
Journal:  Mol Psychiatry       Date:  2002       Impact factor: 15.992

Review 2.  Slow onset of CNS drugs: can changes in protein concentration account for the delay?

Authors:  M J Kuhar; A R Joyce
Journal:  Trends Pharmacol Sci       Date:  2001-09       Impact factor: 14.819

3.  Historical development of the dopamine hypothesis of schizophrenia.

Authors:  Alan A Baumeister; Jennifer L Francis
Journal:  J Hist Neurosci       Date:  2002-09       Impact factor: 0.529

4.  Happy birthday neuroleptics! 50 years later: la folie du doute.

Authors:  Emmanuel Stip
Journal:  Eur Psychiatry       Date:  2002-05       Impact factor: 5.361

5.  Early prediction of antipsychotic response in schizophrenia.

Authors:  Christoph U Correll; Anil K Malhotra; Saurabh Kaushik; Marjorie McMeniman; John M Kane
Journal:  Am J Psychiatry       Date:  2003-11       Impact factor: 18.112

6.  Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.

Authors:  Stefan Leucht; Gabi Pitschel-Walz; Rolf R Engel; Werner Kissling
Journal:  Am J Psychiatry       Date:  2002-02       Impact factor: 18.112

Review 7.  A history of antipsychotic drug development.

Authors:  W W Shen
Journal:  Compr Psychiatry       Date:  1999 Nov-Dec       Impact factor: 3.735

8.  Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.

Authors:  G Perrault; R Depoortere; E Morel; D J Sanger; B Scatton
Journal:  J Pharmacol Exp Ther       Date:  1997-01       Impact factor: 4.030

9.  Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.

Authors:  Steven G Potkin; Anutosh R Saha; Mary J Kujawa; William H Carson; Mirza Ali; Elyse Stock; Joseph Stringfellow; Gary Ingenito; Stephen R Marder
Journal:  Arch Gen Psychiatry       Date:  2003-07

10.  Quantification of D2-like dopamine receptors in the human brain with 18F-desmethoxyfallypride.

Authors:  Gerhard Gründer; Thomas Siessmeier; Markus Piel; Ingo Vernaleken; Hans-Georg Buchholz; Yun Zhou; Christoph Hiemke; Dean F Wong; Frank Rösch; Peter Bartenstein
Journal:  J Nucl Med       Date:  2003-01       Impact factor: 10.057

View more
  39 in total

Review 1.  Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.

Authors:  Leslie Citrome; Richard I G Holt; Daniel J Walker; Vicki Poole Hoffmann
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

2.  Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research.

Authors:  Robert P McMahon; Deanna L Kelly; Douglas L Boggs; Lan Li; Qiaoyan Hu; John M Davis; William T Carpenter
Journal:  Schizophr Bull       Date:  2008-01-08       Impact factor: 9.306

3.  Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study.

Authors:  Parita Shah; Yusuke Iwata; Eric E Brown; Julia Kim; Marcos Sanches; Hiroyoshi Takeuchi; Shinichiro Nakajima; Margaret Hahn; Gary Remington; Philip Gerretsen; Ariel Graff-Guerrero
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-08-19       Impact factor: 5.270

4.  Outcome and length of stay in psychiatric hospitalization, the experience of the University Clinic of Turin.

Authors:  Paola Rocca; C Mingrone; T Mongini; C Montemagni; L Pulvirenti; G Rocca; F Bogetto
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-07-08       Impact factor: 4.328

Review 5.  Guidelines for the Pharmacotherapy of Schizophrenia in Adults.

Authors:  Gary Remington; Donald Addington; William Honer; Zahinoor Ismail; Thomas Raedler; Michael Teehan
Journal:  Can J Psychiatry       Date:  2017-07-13       Impact factor: 4.356

6.  Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial.

Authors:  Marie Stentebjerg-Olesen; Stephen J Ganocy; Robert L Findling; Kiki Chang; Melissa P DelBello; John M Kane; Mauricio Tohen; Pia Jeppesen; Christoph U Correll
Journal:  Eur Child Adolesc Psychiatry       Date:  2015-06-02       Impact factor: 4.785

7.  Neural basis of the potentiated inhibition of repeated haloperidol and clozapine treatment on the phencyclidine-induced hyperlocomotion.

Authors:  Changjiu Zhao; Tao Sun; Ming Li
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-03-26       Impact factor: 5.067

Review 8.  An Integrative Perspective on the Role of Dopamine in Schizophrenia.

Authors:  Tiago V Maia; Michael J Frank
Journal:  Biol Psychiatry       Date:  2016-06-01       Impact factor: 13.382

9.  Clinical outcome and length of stay in an Italian Psychiatric Emergency Service.

Authors:  T Frieri; C Montemagni; G Rocca; P Rocca; V Villari
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2012-10-30       Impact factor: 4.328

10.  The brattleboro rat displays a natural deficit in social discrimination that is restored by clozapine and a neurotensin analog.

Authors:  D Feifel; S Mexal; Gilia Melendez; Philip Y T Liu; Joseph R Goldenberg; Paul D Shilling
Journal:  Neuropsychopharmacology       Date:  2009-03-25       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.